Pediatrics and herpes simplex virus vaccines

Richard Rupp, Susan L. Rosenthal, Lawrence R. Stanberry

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

This review explores the development of prophylactic genital herpes vaccines and their potential impact on perinatal and oral-facial disease. Vaccine strategies have included the use of whole killed virus, viral subunits, attenuated live virus, viral vectors, and bare DNA. To date, the recombinant subunit vaccine, truncated HSV-2 gD and alum/MPL, has been the most efficacious. The vaccine is 73 to 74 percent effective in preventing genital disease in herpes simplex virus seronegative women but is not effective in men or seropositive women. Models predict a significant impact on genital herpes if it limits viral shedding. Reductions in perinatal and oral-facial disease are likely to occur as well. Once an efficacious herpes vaccine is available, its effectiveness will depend ultimately on vaccine acceptance by professional organizations, healthcare professionals, and parents. Further research is required to improve on and fully understand the implications of prophylactic herpes simplex vaccines.

Original languageEnglish (US)
Pages (from-to)31-37
Number of pages7
JournalSeminars in Pediatric Infectious Diseases
Volume16
Issue number1 SPEC.ISS.
DOIs
StatePublished - Jan 2005

Fingerprint

Herpes Simplex Virus Vaccines
Vaccines
Pediatrics
Mouth Diseases
Herpes Genitalis
Viruses
Virus Shedding
Herpes Simplex
Synthetic Vaccines
Subunit Vaccines
Human Herpesvirus 2
Simplexvirus
Parents
Delivery of Health Care
DNA

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)

Cite this

Pediatrics and herpes simplex virus vaccines. / Rupp, Richard; Rosenthal, Susan L.; Stanberry, Lawrence R.

In: Seminars in Pediatric Infectious Diseases, Vol. 16, No. 1 SPEC.ISS., 01.2005, p. 31-37.

Research output: Contribution to journalArticle

Rupp, Richard ; Rosenthal, Susan L. ; Stanberry, Lawrence R. / Pediatrics and herpes simplex virus vaccines. In: Seminars in Pediatric Infectious Diseases. 2005 ; Vol. 16, No. 1 SPEC.ISS. pp. 31-37.
@article{219eeda8e5664d938eec6fb07bc2ba7e,
title = "Pediatrics and herpes simplex virus vaccines",
abstract = "This review explores the development of prophylactic genital herpes vaccines and their potential impact on perinatal and oral-facial disease. Vaccine strategies have included the use of whole killed virus, viral subunits, attenuated live virus, viral vectors, and bare DNA. To date, the recombinant subunit vaccine, truncated HSV-2 gD and alum/MPL, has been the most efficacious. The vaccine is 73 to 74 percent effective in preventing genital disease in herpes simplex virus seronegative women but is not effective in men or seropositive women. Models predict a significant impact on genital herpes if it limits viral shedding. Reductions in perinatal and oral-facial disease are likely to occur as well. Once an efficacious herpes vaccine is available, its effectiveness will depend ultimately on vaccine acceptance by professional organizations, healthcare professionals, and parents. Further research is required to improve on and fully understand the implications of prophylactic herpes simplex vaccines.",
author = "Richard Rupp and Rosenthal, {Susan L.} and Stanberry, {Lawrence R.}",
year = "2005",
month = "1",
doi = "10.1053/j.spid.2004.09.009",
language = "English (US)",
volume = "16",
pages = "31--37",
journal = "Seminars in Pediatric Infectious Diseases",
issn = "1045-1870",
publisher = "W.B. Saunders Ltd",
number = "1 SPEC.ISS.",

}

TY - JOUR

T1 - Pediatrics and herpes simplex virus vaccines

AU - Rupp, Richard

AU - Rosenthal, Susan L.

AU - Stanberry, Lawrence R.

PY - 2005/1

Y1 - 2005/1

N2 - This review explores the development of prophylactic genital herpes vaccines and their potential impact on perinatal and oral-facial disease. Vaccine strategies have included the use of whole killed virus, viral subunits, attenuated live virus, viral vectors, and bare DNA. To date, the recombinant subunit vaccine, truncated HSV-2 gD and alum/MPL, has been the most efficacious. The vaccine is 73 to 74 percent effective in preventing genital disease in herpes simplex virus seronegative women but is not effective in men or seropositive women. Models predict a significant impact on genital herpes if it limits viral shedding. Reductions in perinatal and oral-facial disease are likely to occur as well. Once an efficacious herpes vaccine is available, its effectiveness will depend ultimately on vaccine acceptance by professional organizations, healthcare professionals, and parents. Further research is required to improve on and fully understand the implications of prophylactic herpes simplex vaccines.

AB - This review explores the development of prophylactic genital herpes vaccines and their potential impact on perinatal and oral-facial disease. Vaccine strategies have included the use of whole killed virus, viral subunits, attenuated live virus, viral vectors, and bare DNA. To date, the recombinant subunit vaccine, truncated HSV-2 gD and alum/MPL, has been the most efficacious. The vaccine is 73 to 74 percent effective in preventing genital disease in herpes simplex virus seronegative women but is not effective in men or seropositive women. Models predict a significant impact on genital herpes if it limits viral shedding. Reductions in perinatal and oral-facial disease are likely to occur as well. Once an efficacious herpes vaccine is available, its effectiveness will depend ultimately on vaccine acceptance by professional organizations, healthcare professionals, and parents. Further research is required to improve on and fully understand the implications of prophylactic herpes simplex vaccines.

UR - http://www.scopus.com/inward/record.url?scp=15744362069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15744362069&partnerID=8YFLogxK

U2 - 10.1053/j.spid.2004.09.009

DO - 10.1053/j.spid.2004.09.009

M3 - Article

C2 - 15685147

AN - SCOPUS:15744362069

VL - 16

SP - 31

EP - 37

JO - Seminars in Pediatric Infectious Diseases

JF - Seminars in Pediatric Infectious Diseases

SN - 1045-1870

IS - 1 SPEC.ISS.

ER -